VICO — Vicore Pharma Holding AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK1.74bn
- SEK586.92m
- SEK109.35m
Annual cashflow statement for Vicore Pharma Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -150 | -295 | -291 | -322 | -194 |
| Depreciation | |||||
| Non-Cash Items | 6.2 | 2.1 | 10.6 | 68.7 | 7.92 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 23.4 | 27.5 | -19.8 | -0.217 | 19.1 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -120 | -265 | -300 | -250 | -165 |
| Capital Expenditures | -3 | 0 | -3 | 0 | — |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 7 | -7 | 77 | -144 | 149 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 4 | -7 | 74 | -144 | 149 |
| Financing Cash Flow Items | -10.4 | -17.6 | -12.7 | -29.5 | -48.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 177 | 318 | 187 | 471 | 834 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 61 | 45.6 | -37.4 | 76.8 | 822 |